StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q4 2025
102
Period ended Dec 31, 2025
Change on a year earlier
+3.0%
99 in Q4 2024
History
41 quarters
Since Q4 2015
Sources
37
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMolecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M)Year on yearSource
Q4 2025Dec 31, 2025102+3.0%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 202595+4.4%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 202588-6.4%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 202582-5.7%SEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 202499-9.2%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 202491-4.2%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 202494-4.1%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 202487-13.0%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 2023109-7.6%SEC Filing (0001628280-25-002092) ↗
Q3 2023Sep 30, 202395-19.5%SEC Filing (0001628280-24-042893) ↗
Q2 2023Jun 30, 202398-30.5%SEC Filing (0001628280-24-032182) ↗
Q1 2023Mar 31, 2023100-59.7%SEC Filing (0001628280-24-016497) ↗
Q4 2022Dec 31, 2022118-43.8%SEC Filing (0001628280-24-002009) ↗
Q3 2022Sep 30, 2022118-35.5%SEC Filing (0001628280-23-034544) ↗
Q2 2022Jun 30, 2022141-28.1%SEC Filing (0001628280-23-025156) ↗
Q1 2022Mar 31, 2022248-8.8%SEC Filing (0001628280-23-012020) ↗

Breakdown

What makes up molecular diagnostics (legacy standalone subsegment through fy2025q4 — alinity m) — international revenue ($m)

Cite this data

StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M), quarterly Q4 2015–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-rev-intl

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.